These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9161654)

  • 1. Generalized seizures associated with the use of muromonab-CD3 in two patients after kidney transplantation.
    Seifeldin RA; Lawrence KR; Rahamtulla AF; Monaco AP
    Ann Pharmacother; 1997 May; 31(5):586-9. PubMed ID: 9161654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muromonab-CD3-induced neurotoxicity: report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity.
    Thaisetthawatkul P; Weinstock A; Kerr SL; Cohen ME
    J Child Neurol; 2001 Nov; 16(11):825-31. PubMed ID: 11732768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3).
    Hartnick CJ; Cohen AF; Smith RV
    Ann Otol Rhinol Laryngol; 1997 Aug; 106(8):640-2. PubMed ID: 9270425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet procoagulant activity induced in vivo by muromonab-CD3 infusion in uremic patients.
    Lozano M; Oppenheimer F; Cofan F; Rosinyol L; Mazzara R; Escolar G; Ordinas A
    Thromb Res; 2001 Dec; 104(6):405-11. PubMed ID: 11755950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
    VanderWerf BA
    Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical study of single-dose of recombinant humanized anti-CD3 monoclonal antibody injection in kidney transplant recipients].
    Huang HF; Wu JY; Shou ZF; Zhang JG; Cheng XJ; Liu GJ; Shentu JZ; Wu LH; Li J; Zhou B; Chen JH
    Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(8):516-9. PubMed ID: 21418850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 9. Nursing guidelines for muromonab-CD3 (OKT3).
    Duffy MM; Nestor A
    ANNA J; 1992 Oct; 19(5):493-5. PubMed ID: 1456797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient.
    Go MR; Bumgardner GL
    Transplantation; 2002 Jun; 73(12):1957-9. PubMed ID: 12131696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very early meningoencephalopathy associated with the intraoperative use of OKT3 in renal retransplant.
    Assmann JB; Fontana V; Pansard HM; Ferreira MB; Bianchin MM
    Arq Neuropsiquiatr; 2008 Sep; 66(3B):747-8. PubMed ID: 18949276
    [No Abstract]   [Full Text] [Related]  

  • 12. [Convulsions induced ty OKT3?].
    Merello M; Nogués M; Leiguarda R; Dávalos M; Jost L
    Medicina (B Aires); 1991; 51(6):581. PubMed ID: 7476118
    [No Abstract]   [Full Text] [Related]  

  • 13. Anaphylactoid reaction to muromonab-CD3 in a pediatric renal transplant recipient.
    Berkowitz RJ; Possidente CJ; McPherson BR; Guillot A; Braun SV; Reese JC
    Pharmacotherapy; 2000 Jan; 20(1):100-4. PubMed ID: 10641983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 15. Haemolytic uraemic syndrome associated with OKT3.
    Morris-Stiff G; Evans M; Baboolal K; Balaji V; Moore R; Jurewicz A; Lord R
    Transpl Int; 1996; 9(5):522-3. PubMed ID: 8875800
    [No Abstract]   [Full Text] [Related]  

  • 16. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Ikemiyashiro D; Ocdol H; Mozes M; Anaise D; Johnson C
    Transplant Proc; 1993 Feb; 25(1 Pt 1):572-4. PubMed ID: 8438419
    [No Abstract]   [Full Text] [Related]  

  • 17. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
    First MR
    Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60.
    Xenos EX; Ciancio G; Burke GW; Roth D; Miller J
    Clin Transplant; 1997 Oct; 11(5 Pt 2):497-9. PubMed ID: 9361949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible sensorineural hearing loss following administration of muromonab-CD3 (OKT3) for cadaveric renal transplant immunosuppression.
    Hartnick CJ; Smith RV; Tellis V; Greenstein S; Ruben RJ
    Ann Otol Rhinol Laryngol; 2000 Jan; 109(1):45-7. PubMed ID: 10651411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.
    ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Hack CE
    Transplant Proc; 1996 Dec; 28(6):3217-20. PubMed ID: 8962246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.